What's new

Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Status: Authorised

Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Status: Authorised

Mar 17, 2025 - 16:54
 0
Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Status: Authorised
Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Status: Authorised
Read More

Tags:

Previous Article

Orca Bio to seek approval of T cell transplant after positive trial data

Next Article

Quest Nutrition debuts high-protein shake

Related Posts

Veterinary medicines European public assessment report (EPAR): Tolfenamic acid VMD, Tolfenamic acid, Status: Authorised

Veterinary medicines European public assessment report ...

Feb 9, 2025  0

Human medicines European public assessment report (EPAR): Kavigale, sipavibart, Date of authorisation: 20/01/2025, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 24, 2025  0

Patients' and Consumers' Working Party

Patients' and Consumers' Working Party

Feb 14, 2025  0